Pfizer (PFE) Bids Farewell to Haleon with $3.3B Final Stake Sale
Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...
Fierce Pharma6h
Pfizer pockets roughly £2.5B as it shaves off final stake in consumer health spinoff Haleon
With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...
Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion
Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...
Pharmaceutical Technology on MSN1d
Curevo procures $110m and former-GSK exec for shingles vaccine candidate
Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...
pharmaphorum1d
GSK has most to prove after $16 bn Novartis deal
The biggest vaccine brand it has acquired in the deal is Bexsero, a new vaccine to prevent meningitis B, with a further candidate vaccine in late-stage development, MenABCWY. GSK intends to report ...
Medical Dialogues7h
Pfizer to exit Haleon
Bengaluru: Pfizer will divest its remaining stake in Haleon, marking its complete exit from the British consumer healthcare ...
AllAfrica on MSN2d
Kenya: GSK Rebrands to Haleon Kenya After Separation
Nairobi — UK drugmaker GlaxoSmithKline Limited (GSK) has rebranded to Haleon Kenya Limited, effective March 14, 2025. The rebrand comes after GSK transferred its consumer health business to Haleon to ...